ValuEngine upgraded shares of Calithera Biosciences (NASDAQ:CALA) from a sell rating to a hold rating in a research note issued to investors on Wednesday, June 20th.
Several other brokerages have also issued reports on CALA. Zacks Investment Research lowered shares of Calithera Biosciences from a hold rating to a sell rating in a report on Tuesday, March 13th. Leerink Swann reissued an outperform rating on shares of Calithera Biosciences in a report on Friday, April 6th. One equities research analyst has rated the stock with a sell rating, two have given a hold rating and three have assigned a buy rating to the company. The stock presently has a consensus rating of Hold and a consensus price target of $16.50.
Shares of CALA stock opened at $5.00 on Wednesday. The firm has a market capitalization of $188.18 million, a price-to-earnings ratio of -5.95 and a beta of 2.53. Calithera Biosciences has a one year low of $4.70 and a one year high of $20.05.
Calithera Biosciences (NASDAQ:CALA) last issued its quarterly earnings data on Thursday, May 10th. The biotechnology company reported ($0.37) earnings per share for the quarter, missing the consensus estimate of ($0.32) by ($0.05). Calithera Biosciences had a negative return on equity of 22.92% and a negative net margin of 131.51%. The business had revenue of $5.19 million during the quarter, compared to analyst estimates of $7.28 million. equities research analysts expect that Calithera Biosciences will post -1.4 EPS for the current year.
Several institutional investors have recently added to or reduced their stakes in CALA. BlackRock Inc. increased its stake in Calithera Biosciences by 11.9% during the 1st quarter. BlackRock Inc. now owns 3,229,031 shares of the biotechnology company’s stock valued at $20,344,000 after purchasing an additional 342,756 shares in the last quarter. Millennium Management LLC increased its stake in Calithera Biosciences by 198.6% during the 4th quarter. Millennium Management LLC now owns 1,439,573 shares of the biotechnology company’s stock valued at $12,020,000 after purchasing an additional 957,437 shares in the last quarter. Federated Investors Inc. PA bought a new stake in Calithera Biosciences during the 1st quarter valued at $8,960,000. American Century Companies Inc. increased its stake in Calithera Biosciences by 32.1% during the 1st quarter. American Century Companies Inc. now owns 796,726 shares of the biotechnology company’s stock valued at $5,019,000 after purchasing an additional 193,607 shares in the last quarter. Finally, Ascend Capital LLC grew its stake in shares of Calithera Biosciences by 5.4% in the 4th quarter. Ascend Capital LLC now owns 693,801 shares of the biotechnology company’s stock worth $5,792,000 after acquiring an additional 35,606 shares in the last quarter. Institutional investors own 62.82% of the company’s stock.
About Calithera Biosciences
Calithera Biosciences, Inc, a clinical-stage bio-pharmaceutical company, focuses on the discovery and development of small molecule drugs directed against tumor metabolism and tumor immunology targets for the treatment of cancer in the United States. Its lead product candidate is CB-839, an inhibitor of glutaminase, which is in Phase II clinical trial to treat solid tumors.
To view ValuEngine’s full report, visit ValuEngine’s official website.
Receive News & Ratings for Calithera Biosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Calithera Biosciences and related companies with MarketBeat.com's FREE daily email newsletter.